Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Condition Directory

Multiple Myeloma clinical trials

Directory of U.S. ClinicalTrials.gov public records for Multiple Myeloma. Browse Multiple Myeloma recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 31, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
2318
Shown on this page
12
Current sort
Recently updated
Condition scope
Multiple Myeloma
Additional filters apply within this condition.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

How Multiple Myeloma studies are organized in the registry

Myeloma listings distinguish newly diagnosed from relapsed/refractory disease in their titles, and precursor conditions — smoldering myeloma and MGUS — are usually registered as separate condition terms. Cell-based and antibody platforms (CAR-T, bispecific antibodies) appear by name in many current titles.

Terms that often appear in related listings
relapsed refractory myeloma smoldering myeloma CAR-T bispecific

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Multiple Myeloma. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 505–516 of 2,318 matching trials for Multiple Myeloma.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Active, not recruiting Not applicable Interventional

Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients

NCT04108624
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Screening Phase, Discontinuation Phase
Other · Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 31, 2026, 1:57 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence

NCT02681302
View directory record Official record
Conditions
Multiple Myeloma, Lymphoma
Interventions
Ipilimumab, Nivolumab
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 31, 2026, 1:57 PM EDT
Active, not recruiting Phase 1 Interventional

Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma

NCT05411497
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Autologous MUC1-activated T-cells, Cyclophosphamide
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Phoenix, Arizona • Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 31, 2026, 1:57 PM EDT
Active, not recruiting Phase 3 Interventional

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04975997
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dexamethasone, Daratumumab, Bortezomib, Iberdomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
43
States / cities
Hot Springs, Arkansas • Cerritos, California • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 31, 2026, 1:57 PM EDT
Recruiting Phase 1Phase 2 Interventional

ATRA and Carfilzomib in Plasma Cell Myeloma Patients

NCT06536413
View directory record Official record
Conditions
Multiple Myeloma
Interventions
All-Trans Retinoic Acid (ATRA) Dose 0, All-Trans Retinoic Acid (ATRA) Dose 1
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 31, 2026, 1:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens

NCT01502085
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Vorinostat, Lenalinomide and Dexamethasone
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 31, 2026, 1:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT

NCT01242267
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Thalidomide+Melphalan +Bortezomib+stem cell transplant
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 31, 2026, 1:57 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant

NCT05393804
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ide-cel (bb2121)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 31, 2026, 1:57 PM EDT
Recruiting Phase 1 Interventional

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

NCT05862012
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
ISB 2001
Drug
Lead sponsor
Ichnos Sciences SA
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
Palo Alto, California • Miami, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 31, 2026, 1:57 PM EDT
Recruiting Not applicable Interventional

Survivors Uniting for Remote Guided Exercise

NCT07290309
View directory record Official record
Conditions
Cancer, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Physical Activity, Physical Activity Behavior, Cancer (With or Without Metastasis), Cancer - Chronic Lymphocytic Leukemia, Cancer - Ovarian
Interventions
Virtually Supervised Exercise Sessions, Asynchronous Group
Behavioral
Lead sponsor
Colorado State University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 31, 2026, 1:57 PM EDT
Completed Not applicable Interventional

Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy

NCT05763563
View directory record Official record
Conditions
Lymphoma, Leukemia, Myeloma
Interventions
Resistance Training, Aerobic Exercise, Optional Aerobic Exercise Procedure, Optional In-Person Exercise Sessions
Behavioral · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 31, 2026, 1:57 PM EDT
Recruiting Phase 1 Interventional

Hypofractionation (Radiation) Trial for Multiple Myeloma

NCT06270888
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Radiation
Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 31, 2026, 1:57 PM EDT

About this Multiple Myeloma clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Multiple Myeloma as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Multiple Myeloma.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Multiple Myeloma.